QIAGEN Current Ratio 2010-2022 | QGEN
Current and historical current ratio for QIAGEN (QGEN) from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. QIAGEN current ratio for the three months ending December 31, 2022 was 2.46.
| QIAGEN Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-12-31 |
$2.39B |
$0.98B |
2.46 |
| 2022-09-30 |
$2.76B |
$1.50B |
1.84 |
| 2022-06-30 |
$2.15B |
$0.96B |
2.23 |
| 2022-03-31 |
$2.10B |
$0.96B |
2.19 |
| 2021-12-31 |
$2.11B |
$1.52B |
1.39 |
| 2021-09-30 |
$2.03B |
$1.07B |
1.90 |
| 2021-06-30 |
$1.80B |
$0.50B |
3.58 |
| 2021-03-31 |
$1.67B |
$0.50B |
3.34 |
| 2020-12-31 |
$1.62B |
$0.57B |
2.84 |
| 2020-09-30 |
$1.59B |
$1.09B |
1.46 |
| 2020-06-30 |
$1.64B |
$0.96B |
1.71 |
| 2020-03-31 |
$1.58B |
$1.00B |
1.58 |
| 2019-12-31 |
$1.57B |
$0.95B |
1.65 |
| 2019-09-30 |
$1.54B |
$0.63B |
2.45 |
| 2019-06-30 |
$1.61B |
$0.91B |
1.77 |
| 2019-03-31 |
$1.60B |
$0.94B |
1.69 |
| 2018-12-31 |
$2.16B |
$0.97B |
2.22 |
| 2018-09-30 |
$1.87B |
$1.37B |
1.37 |
| 2018-06-30 |
$1.69B |
$0.94B |
1.79 |
| 2018-03-31 |
$1.75B |
$0.82B |
2.14 |
| 2017-12-31 |
$1.65B |
$0.33B |
5.07 |
| 2017-09-30 |
$1.57B |
$0.30B |
5.33 |
| 2017-06-30 |
$1.16B |
$0.30B |
3.85 |
| 2017-03-31 |
$0.76B |
$0.27B |
2.79 |
| 2016-12-31 |
$1.04B |
$0.31B |
3.36 |
| 2016-09-30 |
$0.96B |
$0.25B |
3.85 |
| 2016-06-30 |
$0.90B |
$0.25B |
3.63 |
| 2016-03-31 |
$0.96B |
$0.25B |
3.91 |
| 2015-12-31 |
$0.96B |
$0.27B |
3.58 |
| 2015-09-30 |
$0.98B |
$0.28B |
3.52 |
| 2015-06-30 |
$0.93B |
$0.27B |
3.51 |
| 2015-03-31 |
$0.96B |
$0.33B |
2.88 |
| 2014-12-31 |
$1.15B |
$0.43B |
2.66 |
| 2014-09-30 |
$1.27B |
$0.44B |
2.91 |
| 2014-06-30 |
$1.20B |
$0.30B |
4.06 |
| 2014-03-31 |
$1.22B |
$0.31B |
3.88 |
| 2013-12-31 |
$0.92B |
$0.34B |
2.73 |
| 2013-09-30 |
$0.87B |
$0.30B |
2.88 |
| 2013-06-30 |
$0.90B |
$0.30B |
3.04 |
| 2013-03-31 |
$0.98B |
$0.27B |
3.66 |
| 2012-12-31 |
$0.99B |
$0.27B |
3.72 |
| 2012-09-30 |
$0.80B |
$0.54B |
1.49 |
| 2012-06-30 |
$0.74B |
$0.51B |
1.45 |
| 2012-03-31 |
$0.76B |
$0.45B |
1.68 |
| 2011-12-31 |
$0.75B |
$0.45B |
1.65 |
| 2011-09-30 |
$0.97B |
$0.65B |
1.50 |
| 2011-06-30 |
$1.41B |
$0.37B |
3.85 |
| 2011-03-31 |
$1.39B |
$0.38B |
3.70 |
| 2010-12-31 |
$1.37B |
$0.39B |
3.51 |
| 2010-09-30 |
$1.35B |
$0.40B |
3.42 |
| 2010-06-30 |
$1.35B |
$0.32B |
4.20 |
| 2010-03-31 |
$1.33B |
$0.34B |
3.94 |
| 2009-12-31 |
$1.33B |
$0.38B |
3.55 |
| 2009-09-30 |
$1.37B |
$0.38B |
3.65 |
| 2009-06-30 |
$0.79B |
$0.26B |
2.97 |
| 2009-03-31 |
$0.71B |
$0.22B |
3.17 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$10.568B |
$2.142B |
|
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
|
